U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07045168) titled 'Risk-adapted Therapeutic Strategy in +1q NDMM' on June 18.
Brief Summary: This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.
Study Start Date: July 04
Study Type: OBSERVATIONAL
Condition:
Multiple Myeloma
Intervention:
OTHER: risk-scoring model
This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16)...